Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

4articles mentioning institutions

13institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: Arm A ×

Arm A

This institution is selected. Its supporting articles are shown below.

Articles mentioning Arm A

4 articles · page 1 of 1

Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

jitc · abstract · 2026-04-24 · 6 matching annotations

90.9%

Arm A Arm B pembrolizumab mCRPC

…Arm A, 24 weeks Arm B, p=0.80). The month 6 PFS rate was 51% in Arm A and 45% in Arm B. Median OS was 2.8 years (2.5 years Arm A, 3.7…

P163 An update regarding the meso-ORIGINS study: part of the PREDICT-meso international accelerator network

thoraxjnl · abstract · 2025-11-02 · 4 matching annotations

93.7%

Arm B Arm A Meso-ORIGINS Pleural Mesothelioma PREDICT-Meso International Accelerator Network PM

… serum proteomics, exhaled breath metabolomics ± perfusion MRI. Arm B (target n=250) patients with suspected PM requiring thoracoscop…

Protocol for Mesothelioma Observational study of Risk prediction and Generation of paired benign-meso tissue samples, Including a Nested MRI Substudy (Meso-ORIGINS)

bmjresp · abstract · 2026-07-01 · 2 matching annotations

86.2%

Arm A Arm B PREDICT-Meso Research Tissue Bank Pleural mesothelioma PREDICT-Meso International Accelerator Network PM

…rising two arms (A and B), with a nested MRI substudy in arm A. Arm A will recruit 300 AAPI patients and perform 6-monthly surveillan…

539 A Phase I, open-label, multicenter, dose escalation and expansion study of HM16390, as a single agent and in combination with pembrolizumab, in patients with advanced or metastatic solid tumors

jitc · abstract · 2025-11-04 · 1 matching annotations

86.0%

Arm A Arm B Institutional Review Board HM16390 pembrolizumab vascular leak syndrome

…n, Dose-Ranging and Dose-Expansion. The Dose-Escalation Part in Arm A (monotherapy) will consist of an accelerated titration design (…